The pursuit of outperformance leads many investors to carefully choose individual stocks. Picking the right ones can be a game-changer for growing your wealth.
The closing price of Repligen Corp (NASDAQ: RGEN) was $143.63 for the day, down -0.77% from the previous closing price of $144.75. In other words, the price has decreased by $-0.77 from its previous closing price. On the day, 0.86 million shares were traded. RGEN stock price reached its highest trading level at $148.21 during the session, while it also had its lowest trading level at $140.14.
Ratios:
Our analysis of RGEN’s different ratios will help us gain a deeper understanding of the company. It provided that stocks Price–to–Cash (P/C) ratio for the trailing twelve months (TTM) is standing at 10.65 whereas its Price-to-Free Cash Flow (P/FCF) for the term is 55.43. For the most recent quarter (mrq), Quick Ratio is recorded 7.28 and its Current Ratio is at 8.41. In the meantime, Its Debt-to-Equity ratio is 0.35 whereas as Long-Term Debt/Eq ratio is at 0.34.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for this company, Evercore ISI on March 18, 2025, initiated with a In-line rating and assigned the stock a target price of $155.
On February 10, 2025, TD Cowen started tracking the stock assigning a Buy rating and target price of $200.
On December 17, 2024, Canaccord Genuity started tracking the stock assigning a Hold rating and target price of $165.Canaccord Genuity initiated its Hold rating on December 17, 2024, with a $165 target price.
Insider Transactions:
Also, insider trades can serve as a great indicator of what management thinks about the future direction of a stock’s price. A recent insider transaction in this stock occurred on Mar 17 ’25 when Hunt Anthony sold 26,756 shares for $152.51 per share. The transaction valued at 4,080,663 led to the insider holds 136,301 shares of the business.
Pax Margaret bought 250 shares of RGEN for $37,672 on Mar 17 ’25. The Director now owns 1,043 shares after completing the transaction at $150.69 per share. On Mar 17 ’25, another insider, Hunt Anthony, who serves as the Director of the company, bought 26,756 shares for $150.42 each.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, RGEN now has a Market Capitalization of 8069004288 and an Enterprise Value of 7993508864. For the stock, the TTM Price-to-Sale (P/S) ratio is 12.71 while its Price-to-Book (P/B) ratio in mrq is 4.08. Its current Enterprise Value per Revenue stands at 12.599 whereas that against EBITDA is 74.497.
Stock Price History:
The Beta on a monthly basis for RGEN is 1.19, which has changed by -0.12527406 over the last 52 weeks, in comparison to a change of 0.097913146 over the same period for the S&P500. Over the past 52 weeks, RGEN has reached a high of $182.52, while it has fallen to a 52-week low of $102.96. The 50-Day Moving Average of the stock is 1.68%, while the 200-Day Moving Average is calculated to be -1.58%.
Shares Statistics:
RGEN traded an average of 771.04K shares per day over the past three months and 775140 shares per day over the past ten days. A total of 56.09M shares are outstanding, with a floating share count of 53.02M. Insiders hold about 5.57% of the company’s shares, while institutions hold 101.12% stake in the company. Shares short for RGEN as of 1744675200 were 3242252 with a Short Ratio of 4.21, compared to 1741910400 on 3795325. Therefore, it implies a Short% of Shares Outstanding of 3242252 and a Short% of Float of 7.7800006.
Dividends & Splits
Against a Trailing Annual Dividend Yield of 0.0
